Meyer Abittan, MD
Cardiology · Roslyn, NYNPI 1548248339
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 41 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 36.7% of the total. Reporting peaked in 2019 at $17,302 and has fallen 89.9% since, to $1,752 in 2025. Among cardiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 542 payments — averaging $52.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$10K
- Regeneron Healthcare Solutions, Inc.$5K
- Amgen$2K
- Johnson & Johnson$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Pfizer$1K
- plus $8K from 35 others
What the payments were for
- Speaking & faculty fees$13,62248%
- Travel & lodging$9113%
- Food & beverage$13,77849%
- Education$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,352 in reported general payments places this provider in the 90th percentile of 112 cardiology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 244 | $338,746 |
| XareltoRivaroxaban | 189 | $236,565 |
| Repatha SureclickEvolocumab | 92 | $81,410 |
| EntrestoSacubitril/Valsartan | 66 | $71,604 |
| MultaqDronedarone Hcl | 38 | $55,940 |
| FarxigaDapagliflozin Propanediol | 62 | $46,162 |
| Inderal LaPropranolol Hcl | 11 | $24,866 |
| Rosuvastatin Calcium | 1,400 | $24,502 |
| BrilintaTicagrelor | 24 | $23,081 |
| LivaloPitavastatin Calcium | 21 | $19,856 |
| Ezetimibe | 541 | $17,290 |
| Metoprolol Succinate | 805 | $15,519 |
| Praluent PenAlirocumab | 22 | $14,205 |
| EdarbiAzilsartan Medoxomil | 23 | $10,680 |
| Ranolazine ErRanolazine | 59 | $8,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $1,101 | $338,746244 claims |
| Johnson & JohnsonXarelto | $1,455 | $236,565189 claims |
| NovartisEntresto | $919 | $71,60466 claims |
| AstraZenecaFarxiga, Brilinta | $932 | $69,24386 claims |
| Sanofi-aventis U.S. LLCMultaq | $10,405 | $55,94038 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $148 | $19,85621 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $202 | $18,47834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 112 cardiology providers in New York.
Other cardiology in Roslyn
- Paul SapiaRoslyn$19K
- Kaupin BrahmbhattRoslyn$13K
- Felix OviasuGarden City$150K
- David D'agateSmithtown$69K
- Michael SiegalNew York$43K
- Michael AvaricioOzone Park$41K
- Bimalkumar BrahmbhattAmityville$31K
- Michael HappesSmithtown$30K
- Perminder GrewalStony Point$19K
- Salim BaghdadiKew Gardens$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.